Innovent Biopharmaceutical Transformation

Robust Pipeline Across Novel Therapeutics - Non-oncology Pipeline 1 commercialized, 1 in pivotal trials and 5 assets in clinical stage Therapeutic Area Commercial Rights Products Target (s) Modality SULINNOⓇ (adalimumab injection) TNF-alpha Monoclonal antibody Autoimmune Worldwide Status Pre-clinical IND Approved Phase 1 Phase 2 Pivotal/ Phase 3 NDA RA, AS, Psoriasis, PJIA, Uveitis IBI-306 PCSK9 Monoclonal antibody Metabolic Mainland China, HK, Taiwan, Macau HOFH HeFH nFH Obesity IBI-362 GLP1/GCGR (OXM3) Polypeptide Metabolic Mainland China, HK, Taiwan, Macau Diabetics IBI-302 VEGF/Complement Fusion protein Ophthalmology IBI-112 IL-23 p19 Monoclonal antibody Autoimmune Worldwide Worldwide WAMD High concentration for wAMD Inflammatory enteritis and other autoimmune diseas Psoriasis Launched IBI-353 PDE4 Small molecule Autoimmune Mainland China, HK, Taiwan, Macau IBI-314 SARS-COV2 S Antibody Cocktail Autoimmune Worldwide Moderate to severe psoriasis (to join Union's global Ph3 study) Moderate to severe atopic dermatitis (to join Union's global Ph3 study) COVID19 (Phase 1/2 ongoing) COVID19 ( Phase 1/2 ongoing) Listed drugs Biologics Small molecules Clinical progress in the U.S. Differentiated non-oncology pipeline represents long-term growth potential in major therapeutic areas including autoimmune, metabolic, and ophthalmology Confidential Copyright©2022 Innovent 28 Innovent Lilly ⚫UNION THERAPEUTICS

View entire presentation